Majken Westergaard

This inventor holds 17 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Santaris Pharma A/s, Enzon Pharmaceuticals, Inc., Roche Innovation Center Copenhagen A/s. Active years: 2009-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Majken Westergaard. Retrieved from https://idiyas.com/inventor/majken-westergaard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 10)

% Patents Active = 29.4

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 4)

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 735(Granted Patents)

Location History:

Birkerød, DK (2010)
Birkerod, DK (2009 - 2018)

Company Filing History:

Enzon Pharmaceuticals, Inc.

patents

7 out of 46

Roche Innovation Center Copenhagen A/s

patents

where one patent can have more than one assignee

Years Active: 2009-2018

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9994850 - Antisense design (2018-06-12),

2. 9951333 - Antisense design (2018-04-24),

3. 9938527 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2018-04-10),

4. 9890383 - Antisense design (2018-02-13),

5. 9708614 - Antisense design (2017-07-18),

6. 9447138 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2016-09-20),

7. 9428534 - Antisense design (2016-08-30),

8. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),

9. 8410071 - Potent LNA oligonucleotides for the inhibition of HIF-1A expression (2013-04-02),

10. 8173428 - LNA oligonucleotides and the treatment of cancer (2012-05-08),

11. 8026355 - Oligomeric compounds for the modulation of survivin expression (2011-09-27),

12. 7939507 - Potent LNA oligonucleotides for the inhibition of HIF-1a expression (2011-05-10),

13. 7741309 - Oligomeric compounds for the modulation of survivin expression (2010-06-22),

14. 7713738 - Oligomeric compounds for the modulation of survivin expression (2010-05-11),

15. 7687617 - Oligonucleotides with alternating segments of locked and non-locked nucleotides (2010-03-30),

Certainly! Here is an article about inventor Majken Westergaard:

Title: Majken Westergaard: Pioneering Innovations in Antisense Therapy

Introduction:

Majken Westergaard, a prolific inventor in the field of pharmaceuticals, hails from Birkerod, Denmark. With an impressive 17 patents to his name, he is a leading figure in the development of novel oligonucleotides for antisense therapy.

Latest Patents:

Westergaard's latest patents revolve around the groundbreaking "Antisense design" - a unique class of pharmaceuticals that incorporate Locked Nucleic Acid (LNA) for enhanced antisense properties. These oligonucleotides, composed of specialized LNAs, show exceptional promise in the realm of antisense therapy for various medical applications.

Career Highlights:

Throughout his career, Majken Westergaard has made significant contributions to companies like Santaris Pharma A/S and Enzon Pharmaceuticals, Inc. His innovative work has paved the way for advancements in drug development and therapeutic solutions.

Collaborations:

Collaborating closely with esteemed colleagues such as Charlotte Albaek Thrue and Henrik Frydenlund Hansen, Westergaard has fostered a culture of innovation and excellence. Together, they have propelled cutting-edge research in the field of pharmaceuticals.

Conclusion:

In conclusion, Majken Westergaard's dedication to pushing the boundaries of pharmaceutical innovation is truly commendable. His inventive approach and collaborative spirit continue to shape the landscape of antisense therapy, offering new hope for patients worldwide.

Profile summary based on public USPTO records.